ROCKVILLE, Maryland / November 19, 2026 — A new kind of malaria vaccine, made from a live malaria parasite that has been genetically disabled so it cannot cause disease, protected 13 of 15 healthy volunteers from malaria infection in a carefully controlled clinical trial, Sanaria Inc. announced today. All seven volunteers who received a placebo became infected, giving the Sanaria® PfSPZ-LARC2 Vaccine an efficacy of 87%.
The results, from a randomized, double-blind, placebo-controlled Phase 1 trial at the University of Washington, were presented today by Dr. Sean C. Murphy of the University of Washington School of Medicine and Seattle Children’s Hospital at the annual meeting of the American Society of Tropical Medicine and Hygiene in National Harbor, Maryland.
The protection held up under demanding conditions. Volunteers were exposed to malaria three to four months after their last dose, and to a parasite strain genetically different and from a different continent than the one used to make the vaccine — a tough test that better reflects the real world, where many strains circulate.
This is the first time an injectable vaccine of this type, a weakened parasite engineered to grow in the liver until late in its development and then stop, has been tested for its ability to prevent malaria infection in people. Sanaria has pursued this approach for more than a decade, aiming for a vaccine that blocks infection outright rather than only reducing how sick people get.
Why it matters
Malaria infected an estimated 282 million people and killed about 610,000 in 2024, according to the World Health Organization’s World Malaria Report 2025. About 95% of those deaths were in Africa, most of them among children under five. A vaccine that prevents infection altogether, rather than lessening its severity, could both protect the person vaccinated and help stop the parasite from spreading — a key step toward eliminating the disease.
The results at a glance
- 87% efficacy. Two of 15 vaccinated volunteers became infected, compared with all seven placebo recipients (95% confidence interval: 60–99%).
- Protection against a different strain, months later. Volunteers were exposed three to four months after their final dose to 7G8, a parasite strain from South America genetically distant from the strain from Africa used to make the vaccine.
- Lower parasite levels when protection was incomplete. The two vaccinated volunteers who became infected had fewer parasites in their blood over the course of infection than placebo recipients.
- Safe and well tolerated, with no vaccine-related serious adverse events. The weakened vaccine parasite never once escaped the liver.
- Strong, lasting immune responses, including the “killer” T cells thought to be central to destroying infected liver cells.
- Every volunteer who became infected was promptly and successfully treated.
How the trial worked
Twenty-two healthy adults aged 18 to 45 who had never had malaria were randomly assigned to receive either the vaccine or a saltwater (saline) placebo; neither the volunteers nor the study team knew who received which. Each person received three injections 28 days apart.
Three to four months after the last dose, every participant was deliberately exposed to malaria parasites under close medical supervision. This well-established research method, called controlled human malaria infection, lets scientists measure protection directly: volunteers are monitored with a highly sensitive blood test so that any infection is detected early and treated right away.
How the vaccine works
Malaria begins when an infected mosquito bites and injects a form of the parasite called a sporozoite. Sporozoites travel to the liver, multiply there for about a week, and then burst into the bloodstream, where they invade red blood cells and cause the fever, illness and deaths associated with malaria.
PfSPZ-LARC2 Vaccine is made of live sporozoites of Plasmodium falciparum, the deadliest human malaria parasite, from which two genes, PfMei2 and PfLINUP, have been removed. At first the engineered parasite behaves like a normal one: it enters the liver and grows, showing the immune system the full range of parasite proteins it would encounter in a real infection. But late in its liver stage it stalls and dies. It never produces the forms needed to invade red blood cells, so it cannot cause malaria illness and cannot be passed on by mosquitoes.
Because it develops so far before stopping, the vaccine gives the immune system a much richer look at the parasite than earlier weakened-parasite vaccines that stop early in the liver. Sanaria designed it on the premise that this richer exposure would produce stronger protection. These results support that idea.
The PfLARC2 parasite strain was created in Dr. Stefan Kappe’s laboratory at Seattle Children’s, with co-inventors Dr. Debashree Goswami and Dr. Ashley Vaughan. (Dr. Kappe is now director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine in Baltimore.) The strain is exclusively licensed to Sanaria Inc., which developed it into a vaccine, manufactured it and advanced it into clinical testing. The underlying preclinical work was published in EMBO Molecular Medicine in 2024.
Safety: the vaccine parasite stayed in the liver
The trial’s primary goal was safety — above all, confirming that the two gene deletions reliably stop the parasite in the liver. Across 46 vaccinations, delivering a total of about nine million parasites, the vaccine parasite never once escaped into the bloodstream.
There were no vaccine-related serious adverse events and no vaccine-related severe (Grade 3 or higher) side effects, whether reported spontaneously by volunteers or asked about specifically at the injection site and elsewhere in the body. One vaccine-related laboratory finding reached Grade 3: a temporary drop in a type of white blood cell (neutrophils) one week after the second dose.
Immune responses
The vaccine produced the expected antibodies against the parasite’s main surface protein (PfCSP), along with strong and lasting responses from two kinds of T cells: CD4+ “helper” T cells, which coordinate the immune response, and CD8+ “killer” T cells. These responses were directed against both the sporozoite form of the parasite and infected red blood cells.
The CD8+ T cell results are especially encouraging. Protection from Sanaria’s whole-parasite vaccines is thought to depend largely on killer T cells finding and destroying infected liver cells before the parasite can reach the blood — and in this trial, those responses held steady over time.
What they’re saying
“For more than twenty years, we have worked on the premise that a whole-parasite vaccine, one that shows the immune system thousands of parasite proteins instead of one or two, is what it will take to stop malaria infection, not just soften it,” said Dr. Stephen L. Hoffman, CEO of Sanaria Inc. “Eighty-seven percent protection against a different strain, three to four months after the last dose, from a vaccine parasite that never once escaped the liver, is the clearest signal we have had that the premise is right. The work now, which is already underway, is to show the same protection in the people who suffer from malaria.”
“We engineered the PfLARC2 strain to be a safe vaccine that stimulates a superior immune response against malaria parasites in the liver,” said Dr. Kappe. “It is truly rewarding to see that this vaccine is safe, and how well it protected volunteers against a highly divergent malaria strain in the Seattle trial.”
“Manufacturing a live, genetically attenuated parasite to the standard required for injection into people took years, and it is the part of this effort that is easiest to overlook,” said Dr. B. Kim Lee Sim, Executive Vice President of Process Development and Manufacturing at Sanaria Inc. “Forty-six vaccinations without a single vaccine parasite escaping the liver tells us the attenuation is doing exactly what it was designed to do, lot after lot.”
“The next questions are the ones that decide whether this becomes a public health tool: how it performs in people who have been exposed to malaria all their lives, and what the best dose and schedule are,” said Dr. Thomas L. Richie, Chief Medical Officer of Sanaria Inc. “Those studies are underway.”
What comes next
Sanaria is now focused on testing PfSPZ-LARC2 Vaccine in places where malaria is common and on finding the best dosing regimen. The vaccine has completed Phase 1 trials in Burkina Faso and the United States and is in a Phase 1 trial in Germany and Phase 2 trials in Burkina Faso and Mali. More detailed immune analyses from the Seattle trial are underway, and the final clinical study report, with further data, is expected in the first quarter of 2027.
About the trial
The trial (VTEU 23-0010; ASTMH abstract #6481) was conducted at the University of Washington Vaccine and Treatment Evaluation Unit, with Dr. R. Scott McClelland as clinical site principal investigator and Drs. Sean C. Murphy and Jim Kublin as co-principal investigators. Enrollment began in July 2025; all participants were vaccinated between July and October 2025 and underwent controlled human malaria infection in January 2026. Efficacy was assessed by Pf 18S rRNA RT-PCR at the UW Medicine Malaria Molecular Diagnostic Laboratory, directed by Dr. Murphy. Intracellular cytokine staining was performed at Fred Hutch Cancer Center.
The study (NCT06735209) was conducted by the Infectious Diseases Clinical Research Consortium (UM1AI148684) and the Vaccine and Treatment Evaluation Unit at the University of Washington School of Medicine (UM1AI148573), supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, which sponsored the trial. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Sanaria thanks the study participants and the entire Seattle study team.
Competing interests: Several authors are employees of Sanaria Inc.; B. Kim Lee Sim and Stephen L. Hoffman own stock in Sanaria.
Media contacts
Sanaria Inc. — sanaria@sanaria.com, +1 301-770-3222
About Sanaria Inc.
Founded in 2003, Sanaria is committed to developing groundbreaking malaria vaccines, offering sustained protection against Plasmodium falciparum. Headquartered in Rockville, Maryland, we are a leader in malaria vaccine innovation. Our name—drawn from the Italian malaria (“bad air”)—symbolizes our mission to bring a breath of healthy air to the fight against malaria, with vaccines designed not only to prevent disease, but also to interrupt transmission and enable targeted elimination. With over $430M invested to date, Sanaria has secured 79 worldwide patents with 14 applications pending. The company is actively seeking partners to further advance its vaccine technologies. Learn more at sanaria.com.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve known and unknown risks and uncertainties, which may cause actual results to differ materially from anticipated results or achievements expressed or implied by the statements made. Such statements include the availability of an effective vaccine, the expectations for eliminating malaria, and beliefs concerning the suitability of a successful vaccine. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company’s ability to raise sufficient funds, the regulatory approval process, clinical trials results, the Company’s patent portfolio, dependence on key personnel and other risks associated with vaccine development. For further information contact sanaria@sanaria.com or call 301-770-3222.